Efficacy and safety of a fixed-dose combination of D-norpseudoephedrine, triiodothyronine, atropine, aloin, and diazepam in obese patients

Objective: A fixed-dose combination (FDC) of D-norpseudoephedrine, triiodothyronine, atropine, aloin, and diazepam is used in Mexico for the short-term treatment of obesity; however, its efficacy and safety have been scarcely studied. The aim of this study was to analyze the efficacy and safety of this FDC in Mexican adult overweight and obese patients by a prospective, uncontrolled, multicenter, phase IV open-label study. Materials and methods: 3,290 patients with a body mass index (BMI) ? 27 kg/m2 were included in the current study. Primary outcome was the absolute body weight loss, whilst secondary outcomes were the improvement of anthropometric and cardiometabolic parameters as well as the description of adverse events. Results: The FDC decreased the body weight and BMI by-9.0 ? 5.6 kg and-3.4 ? 2.2 kg/m2, respectively, at 6 months. In addition, 43.3% and 14.3% of subjects achieved at least 5% or 10% weight loss at 6 months, respectively. The FDC also significantly improved waist circumference, hip circumference, body fat, visceral fat, systolic blood pressure, diastolic blood pressure, diabetes risk, and mortality risk, at 3 and 6 months. Moreover, the FDC seems to have better results in the following order: obese grade 3 ? Obese grade 2 ? Obese grade 1 ? Overweight patients. Mild mouth dryness, anxiety, and headache were the main reported adverse events. Conclusion: Data suggest that the FDC is effective and well tolerated for the short-term therapy of overweight and obesity in Mexican patients.